The
basic leucine zipper transcription factor CCAAT/enhancer binding protein-beta (
C/EBPbeta) is expressed in many cell types, including keratinocytes.
C/EBPbeta activity can be increased by phosphorylation through pathways stimulated by oncogenic Ras, although the
biological implications of Ras-
C/EBPbeta signaling are not currently understood. We report here that
C/EBPbeta-nullizygous mice are completely refractory to skin
tumor development induced by a variety of
carcinogens and
carcinogenesis protocols, including 7,12-dimethylbenz[a]
anthracene-initiation/12-O-tetradecanoylphorbol 13-acetate promotion, that produce
tumors containing oncogenic Ras mutations. No significant differences in TPA-induced epidermal keratinocyte proliferation were observed in
C/EBPbeta-null versus wild-type mice. However, apoptosis was significantly elevated (17-fold) in the epidermal keratinocytes of 7,12-dimethylbenz[a]
anthracene-treated
C/EBPbeta-null mice compared with wild-type mice. In v-Ha-ras transgenic mice,
C/EBPbeta deficiency also led to greatly reduced skin
tumor multiplicity and size, providing additional evidence for a
tumorigenesis pathway linking Ras and
C/EBPbeta. Oncogenic Ras potently stimulated
C/EBPbeta to activate a C/EBP-responsive promoter-reporter in keratinocytes and mutating an ERK1/2 phosphorylation site (T188) in
C/EBPbeta abolished this Ras effect. Finally, we observed that
C/EBPbeta participates in oncogenic Ras-induced transformation of NIH 3T3 cells. These findings indicate that
C/EBPbeta has a critical role in Ras-mediated
tumorigenesis and cell survival and implicate
C/EBPbeta as a target for
tumor inhibition.